653 related articles for article (PubMed ID: 28898890)
1. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
[TBL] [Abstract][Full Text] [Related]
2. An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002).
Gotfried MH; Girod CE; Antin-Ozerkis D; Burgess T; Strombom I; Stauffer JL; Kirchgaessler KU; Padilla ML
Pulm Ther; 2018 Jun; 4(1):59-71. PubMed ID: 32026243
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
Valeyre D; Albera C; Bradford WZ; Costabel U; King TE; Leff JA; Noble PW; Sahn SA; du Bois RM
Respirology; 2014 Jul; 19(5):740-7. PubMed ID: 24836849
[TBL] [Abstract][Full Text] [Related]
4. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
Behr J; Nathan SD; Costabel U; Albera C; Wuyts WA; Glassberg MK; Haller H; Alvaro G; Gilberg F; Samara K; Lancaster L
Adv Ther; 2023 Sep; 40(9):3937-3955. PubMed ID: 37391667
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
7. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.
Lancaster L; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; King TE; Lederer DJ; Lin Z; Nathan SD; Pereira CA; Swigris JJ; Valeyre D; Noble PW
BMJ Open Respir Res; 2016; 3(1):e000105. PubMed ID: 26835133
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
9. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
[TBL] [Abstract][Full Text] [Related]
13. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
Costabel U; Albera C; Glassberg MK; Lancaster LH; Wuyts WA; Petzinger U; Gilberg F; Kirchgaessler KU; Noble PW
Respir Res; 2019 Mar; 20(1):55. PubMed ID: 30866942
[TBL] [Abstract][Full Text] [Related]
14. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
[TBL] [Abstract][Full Text] [Related]
15. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.
Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V
Respiration; 2019; 98(1):19-28. PubMed ID: 30965332
[TBL] [Abstract][Full Text] [Related]
16. Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.
Wijsenbeek MS; Grutters JC; Wuyts WA
Adv Ther; 2015 Jul; 32(7):691-704. PubMed ID: 26173796
[TBL] [Abstract][Full Text] [Related]
17. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
Yoon HY; Kim DS; Song JW
Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
[TBL] [Abstract][Full Text] [Related]
20. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
Dhooria S; Agarwal R; Sehgal IS; Prasad KT; Muth V; Garg M; Bal A; Aggarwal AN; Behera D
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):148-157. PubMed ID: 33093778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
